`
`Charles M. Lizza
`William C. Baton
`SAUL EWING ARNSTEIN & LEHR LLP
`One Riverfront Plaza, Suite 1520
`Newark, New Jersey 07102-5426
`(973) 286-6700
`clizza@saul.com
`
`Attorneys for Plaintiffs
`Celgene Corporation and
`Abraxis Bioscience, LLC
`
`Arnold B. Calmann
`Katherine A. Escanlar
`SAIBER LLC
`One Gateway Center
`10th Floor, Suite 1000
`Newark, New Jersey 07102
`(973) 622-333
`
`Attorneys for Defendant
`Cipla Limited
`
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`
`
`
`ABRAXIS BIOSCIENCE, LLC and
`CELGENE CORPORATION,
`
`
`Plaintiffs,
`
`Defendant.
`
`v.
`
`
`CIPLA LTD.,
`
`
`
`
`
`
`
`
`
`
`Civil Action No. 16-9074 (JMV)(MF)
`
`(Filed Electronically)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`JOINT CLAIM CONSTRUCTION AND PREHEARING STATEMENT
`
`Plaintiffs Abraxis Bioscience, LLC and Celgene Corporation (collectively, “Celgene”)
`
`and Defendant Cipla Ltd. (“Cipla”) hereby submit their Joint Claim Construction and Prehearing
`
`Statement in accordance with Local Patent Rule 4.3. At this time, there are no disputed claim
`
`terms requiring construction by the Court.
`
`
`
`
`
`
`
`
`
`Case 2:16-cv-09074-JMV-MF Document 78 Filed 11/21/17 Page 2 of 3 PageID: 778
`
`I.
`
`CONSTRUCTION OF PATENT TERMS
`
`A.
`
`Agreed Upon Claim Constructions
`
`Pursuant to Local Patent Rule 4.3(a), the parties identify the following terms on which
`
`the parties agree for the purposes of this proceeding only. To the extent that the claim terms
`
`are used repeatedly throughout a patent or family of patents, any constructions of such terms
`
`carry the same meaning throughout a patent or family of patents.
`
`Term
`
`Patent(s)
`
`Definition
`
`The weight ratio of albumin
`to paclitaxel in the final
`product for injection into the
`patient
`
`U.S. Patent No. 7,820,788,
`claims 1, 11, and 12
`
`U.S. Patent No. 7,923,536,
`claims 1, 5, 6, 9, and 10
`U.S. Patent No. 8,138,229,
`claims 1, 4-5, 9-10, 15, 17-
`18, 25-26, 31-32, and 40-41
`
`“the weight ratio of albumin
`to paclitaxel in the
`composition”
`
`“the weight ratio of albumin
`to the paclitaxel in the
`composition”
`
`“the ratio (w/w) of albumin
`to the paclitaxel in the
`pharmaceutical composition”
`
`“the ratio (w/w) of the
`albumin to the paclitaxel in
`the pharmaceutical
`composition”
`
`B.
`
`Disputed Claim Terms
`
`The parties submit that there are no disputed claim terms requiring construction by the Court.
`
`2
`
`
`
`Case 2:16-cv-09074-JMV-MF Document 78 Filed 11/21/17 Page 3 of 3 PageID: 779
`
`
`
`Respectfully submitted,
`
`By: s/ Arnold B. Calmann
`Arnold B. Calmann
`Katherine A. Escanlar
`SAIBER LLC
`One Gateway Center
`10th Floor, Suite 1000
`Newark, New Jersey 07102
`(973) 622-333
`
`OF COUNSEL:
`Anil H. Patel
`Peter Giunta
`Ravi S. Deol
`Michael J. Freno
`Elizabeth Weiskopf
`K&L GATES LLP
`1000 Main St. Ste. 2550
`Houston, TX 77002
`(713)815-7300
`
`
`
`Attorneys for Defendant
`Cipla Limited
`
`Dated: November 21, 2017
`
`Respectfully submitted,
`
`By: s/ Charles M. Lizza
`Charles M. Lizza
`William C. Baton
`SAUL EWING ARNSTEIN & LEHR LLP
`One Riverfront Plaza, Suite 1520
`Newark, NJ 07102-5426
`(973) 286-6700
`clizza@saul.com
`
`OF COUNSEL:
`F. Dominic Cerrito
`Eric C. Stops
`Andrew S. Chalson
`Daniel Wiesner
`Catherine T. Mattes
`Ross Misskelley
`QUINN EMANUEL URQUHART &
`SULLIVAN LLP
`51 Madison Avenue, 22nd Floor
`New York, New York 10010
`(212) 849-7000
`
`Anthony M. Insogna
`Cary Miller, Ph.D.
`Steven J. Corr
`JONES DAY
`12265 El Camino Real #200
`San Diego, CA 92130
`(858) 314-1200
`
`
`
`
`
`
`
`
`Attorneys for Plaintiffs
`Celgene Corporation and
`Abraxis BioScience, LLC
`
`3
`
`